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carbidopa intestinal gel
Stephen W Pedersen1, Martin 
Suedmeyer2, Louis W C Liu3, 
Dirk Domagk4, Alison Forbes5, 
Lars Bergmann6, Koray Onuk6, 
Ashley Yegin6, Teus van Laar7
1Department of Neurology, Glostrup Hospital, 
University of Copenhagen, Glostrup, Copenhagen, 
Denmark; 2Department of Neurology, University 
of Düesseldorf, Düesseldorf, Germany; 3Division 
of Gastroenterology, Department of Medicine, 
University of Toronto, University Health Network, 
Toronto, ON, Canada; 4Department of Medicine 
I, Josephs-Hospital Warendorf, Academic Teaching 
Hospital, University of Muenster, Warendorf, 
Germany; 5PDNS consultant, AbbVie Inc., 
Roswell, GA, USA; 6Global Medical Affairs, AbbVie 
Inc., North Chicago, IL, USA; 7Department of 
Neurology, University Medical Center Groningen, 
Groningen, The Netherlands
Abstract: A multidisciplinary team (MDT) approach is increasingly recommended in Parkin-
son’s disease (PD) treatment guidelines, but no standard of care exists for such an approach, 
and the guidelines do not provide clarification on how it should be implemented. This paper 
reviews evidence of MDT interventions in people with PD and provides expert clinical perspec-
tives for an MDT approach, with a focus on advanced PD and levodopa–carbidopa intestinal 
gel (carbidopa–levodopa enteral suspension in the USA). The key recommendations are to 
enable the best possible treatment of people with PD locally by facilitating a close structured 
collaboration of different health care professionals working in a fixed network structure; to refer 
people with PD to established MDT centers in a timely manner; to establish regular meetings 
for the MDT enabling interdisciplinary exchange and learning; to optimize individual treatment 
and carefully evaluate available treatment options; to ensure treatment decisions are agreed 
jointly between people with PD, their caregivers, family, and health care professional; and to 
include specialists outside of neurology from adjuvant medical departments as necessary when 
implementing advanced therapies.
Keywords: Parkinson’s disease, multidisciplinary team, advanced therapy, levodopa–carbidopa 
intestinal gel, carbidopa–levodopa enteral suspension
Introduction
A multidisciplinary team (MDT) approach has been shown to improve the quality of 
life (QoL)1–5 and motor function1,2,4–8 for people with Parkinson’s disease (PD) and 
QoL for their caregivers.9–11 Although limited studies are available, it is clear that 
people with PD benefit from such an approach (Table 1), and as such, it is increasingly 
recommended in PD treatment guidelines.12,13 Up to 20 different health care profes-
sionals may provide beneficial interventions,14 but no standard of care exists for an 
MDT approach, and the guidelines do not provide clarification on how it should be 
implemented. As a result, although the prevalence of PD increases with age to nearly 
2% (1,903/100,000) in those over 80 years of age worldwide,15 many people with PD 
receive suboptimal management.
The lack of a clear definition of advanced PD16 creates a further challenge. 
Furthermore, people who have been identified as having advanced PD are often 
not referred for advanced therapies,17 which can improve their motor function and 
QoL.18 These therapies – deep brain stimulation (DBS),19 subcutaneous apomorphine 
pump,20 and levodopa–carbidopa intestinal gel (LCIG; carbidopa–levodopa enteral 
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suspension in the USA),21 – require specialized MDTs to 
ensure successful implementation. However, experience in 
establishing and working within such specialized MDTs 
is limited.
This paper reviews the literature and shares the extensive 
relevant experiences of the authors to help address gaps in 
clinical practice and guidelines concerning MDT manage-
ment of advanced PD, timely referral of people with PD for 
advanced therapies, and implementation of advanced thera-
pies (with special attention to LCIG therapy).
Literature search strategy and 
selection criteria
Studies were identified through a PubMed literature search 
using the following search terms: multidisciplinary/inter-
disciplinary/multispecialty AND Parkinson’s disease AND 
study. This yielded 90 hits – the abstracts were screened for 
suitability. Only studies investigating the impact of multi-
disciplinary care in people with PD were included. Reviews 
(systematic and other), nonrelevant articles, and studies in 
which only the protocol and study design were discussed 
were excluded from the results. The literature search was 
performed in July 2016.
Who is in the MDT?
The MDT comprises up to 20 different collaborating health 
care professionals centered on the person with PD and 
their caregiver, to provide comprehensive care to meet as 
many of the patient’s health and other needs as possible 
(Table 2).12,14,22 The involvement of a PD nurse specialist 
(PDNS),12,14,22,23 to offer support at the individual level, 
education to the wider community, and training of clinical 
and nonclinical staff,24 complements the interventions of 
the rest of the team to improve the QoL of people with PD 
and their caregivers.25
As PD progresses to advanced PD,26 device-aided 
advanced therapies become an option to improve motor func-
tion and QoL.18 At this stage, additional members of the MDT 
include neurosurgeons and gastroenterologists with a special 
interest and expertise in managing people with advanced PD 
indicated for DBS or LCIG, respectively.
Roles and responsibilities within 
the MDT
The PD MDT composition and the roles/responsibilities of 
each member require clear definition so that they can work 
both individually and collaboratively to achieve a common set 
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MDT management for advanced PD
People with PD and their caregivers require clear 
information and education about their therapeutic options 
throughout the disease, including the possible advantages 
and disadvantages, to ensure that treatments are used appro-
priately to achieve the best possible QoL and motor func-
tion.17,27 The MDS and PDNS are experts in the provision of 
such information, and all newly diagnosed people with PD 
should be referred to a specialized MDT with a PDNS as 
soon as possible after diagnosis.17,24,27 The PDNS can then 
liaise with and involve the MDS and other members of the 
MDT as required.
The MDS and PDNS aim to provide seamless care and 
information and provide newly diagnosed people with PD 
with the opportunity to talk about and discuss the diagnosis 
in more detail. They can help them come to terms with the 
diagnosis, how it might affect them, and how they can man-
age it.24
Caregivers also play an important role in the team of indi-
viduals supporting people with PD. While offering assistance 
with activities of daily living, they are also involved with the 
management of PD-related tasks (appointments, medication) 
and treatment decisions. At all stages of the disease, treatment 
decisions should be made jointly between the person with PD, 
their caregiver, family, and health care practitioners.28 Greater 
involvement in treatment decisions leads to significantly 
greater satisfaction and distress relief in people with PD.29 
Furthermore, engaging people with PD and their caregivers 
to understand PD and the therapies available could lead to 
improved adherence to therapy, as has been demonstrated in 
diabetes patients.30
A further role for the MDS and PDNS is to dis-
cuss advanced therapies with people with PD and their 
 caregivers early in the disease course. To avoid “end-stage” 
perception, it is important they highlight that there may be 
a time when existing therapies are no longer effective, and 
at this point advanced therapies may offer much-needed 
improvements in QoL and motor function.21,31–33 They can 
then discuss with the MDS how to derive maximum ben-
efit from such treatment when it becomes the appropriate 
option.
Identification of people with PD for 
advanced therapy, and selection and 
implementation of the appropriate 
therapy
Treatment with oral dopaminergic therapies usually con-
trols motor symptoms in early PD, but as PD progresses 
it becomes less effective, resulting in motor and nonmotor 
Table 2 Members of the MDT listed by the European Parkinson’s 
Disease Standards of Care Consensus Statement and their role in 
the care and management of people with PD12
MDT member Role
General practitioner To provide day-to-day clinical management
Movement disorder 
specialist/neurologist
To plan and monitor treatment
Geriatrician To provide general in- and outpatient 
management
PDNS To manage care and coordinate with the 
hospital and community services
Physiotherapist To maximize functional ability
Speech and language 
therapist
To manage difficulties with speech, 
communication, eating, drinking, and 
swallowing
Occupational therapist To advise on measures to retain 
independence
Nutritionist To ensure optimal nutrition
Psychologist To treat depression, other mental health 
problems
Pharmacists To ensure supplies of specialist medications
Complementary 
therapists
To provide massage and relaxation therapies
Note: Data from The European Parkinson’s Disease Standards of Care Consensus 
Statement.12
Abbreviations: PD, Parkinson’s disease; MDT, multidisciplinary team; PDNS, 
Parkinson’s disease nurse specialist.
members at any one time depends on the needs of the person 
with PD and their caregiver, and the stage of their disease. 
Effective interventions preserve the caregiver’s well-being, 
and allow people with PD to remain at home with appropri-
ate assistance.9
Ideally, various networks exist and interact within the 
MDT (Figure 1A). In Denmark, for example:
1. A triangular network exists for day-to-day management 
between general community nurses, a key community 
nurse trained in PD who can answer most day-to-day 
questions, and a hospital-based PDNS.
2. A vertical network provides nurses in the community with 
access to expert advice and information from the PDNS 
and neurologist.
3. Horizontal networks in the hospital facilitate treatment 
of advanced PD between movement disorder specialists 
(MDSs)/specialist neurologists, gastroenterologists, 
and neurosurgeons, and between nurses from different 
departments.
The complex, but not complicated, multidisciplinary 
Glostrup model (Figure 1B) depicts the interactions and 
networks between all members of the PD MDT with the 
person with PD, their caregiver, the MDS, and the PDNS 
at the center. A strong collaboration between hospital and 
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Figure 1 Examples of multidisciplinary team networks aiming to provide comprehensive and collaborative care for people with PD.
Notes: (A) Network interaction within the PD multidisciplinary team in Denmark supporting information exchange about patients. (B) The Rigshospitalet Glostrup model.
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MDT management for advanced PD
fluctuations and dyskinesias.34 The reasons for this are poorly 
understood, but probably involve pharmacokinetic factors.35 
The progression of PD has a substantial impact on health-
related QoL.36 During long-term follow-up, deterioration in 
physical mobility has been shown to be the most important 
factor contributing to decline in health-related QoL.37 A 
relationship between QoL for the person with PD and the 
caregiver’s perceived burden has also been demonstrated.38 At 
this stage of PD, it is important to ensure timely referral to an 
MDS before complications develop and QoL deteriorates.17
Advanced therapies may be appropriate when motor 
fluctuations become refractory to adjustments in oral and 
transdermal medications and when such adjustments are 
complicated by the emergence (or worsening) of dyskine-
sias.39,40 Simplified criteria to help improve recognition of 
the advanced stages of PD despite an optimized oral drug 
regimen can include:
1. unpredictable fluctuations;
2. more than 2 hours “off ”-time/d;
3. over five doses of medication/d;
4. impaired activities of daily living.18
Raising awareness about when a person with PD might 
benefit from an advanced therapy is a key responsibility 
for the MDS. The PDNS, in providing individual care to 
alleviate the impact of PD on daily life, is well placed to 
assess whether a patient might derive more autonomy with 
an advanced therapy.41
Once the MDS has identified that a person with PD might 
benefit from an advanced therapy, he or she can discuss the 
options, advantages, and disadvantages of each treatment, 
and advise on how the advanced therapy can improve the 
patient’s symptoms. The PDNS can help the patient and 
their caregiver take an active role in the decision-making 
process,24,41 for example, by providing a portable test pump 
and tubing so that the person with PD can experience how it 
might feel to wear and carry it every day.
The PDNS and MDS aim to align the expectations of the 
person with PD and their caregiver with what can be achieved 
from a particular type of advanced therapy.
The regional MDT approach in the 
Netherlands (ParkinsonNet) improves 
quality of care and reduces health care 
costs
In the Netherlands, regional MDTs specialize in providing 
a particular type of advanced PD therapy.42 Such regional 
cooperation has improved the quality of care and reduced 
health care costs for people with PD.43
All teams meet together regularly to discuss those people 
with PD who might have an indication for advanced therapy 
in their area and to exchange experience and knowledge. 
These meetings involve 10–15 MDSs and 10–15 PDNSs 
from the university hospital and the larger regional hospi-
tals in the area. Decisions are made on the most suitable 
advanced therapy for each individual with PD using a matrix 
(Table 3) that takes into account medical conditions, for 
example, impaired cognitive function. Recently published 
expert opinion recommendations give some guidance on 
the management of people with mild or moderate cognitive 
impairment.18
ParkinsonNet (Nijmegen, the Netherlands) is also largely 
focused on “participatory medicine”, encouraging people 
with PD to take an active role in the management of their 
disease and act as partners in the decision-making process.28 
They are then referred to a center, providing the chosen 
therapy, close to their home. To enable this collaboration, 
patients need to be well-informed and empowered to make a 
choice, through the provision of unbiased medical informa-
tion presented in a way that can be easily understood.28 This 
collaboration requires physicians to “guide” patients, rather 
than telling them what to do.28 A decision aid to support 
people with PD make a choice about advanced therapies is 
being developed and was recently trialed with 19 patients.44 
Overall, 100% of the participants stated that they would use 
the aid if faced with the choice, with 88% saying that the 
information was well balanced. The aid is currently being 
Table 3 Matrix used in the Netherlands to help decide upon the 
most suitable advanced therapy for each individual with PD
Factor Apomorphine LCIG DBS
Age >75 years 0 0 –
Postural instability 0 0 –
Hallucinations –/+ –/0 –
ICD –/+ + +
Excessive daytime sleepiness – 0 0
Dementia 0 0 –
Need to stop oral medication – + –
Moderate depression + +/0 –
Suicide attempts 0 0 –
Restless legs + + 0/–
Weight gain 0 0 –
Notes: +, factor strengthens the decision to select the device-aided therapy; 0, 
factor does not influence the decision; –, factor argues against selecting the device-
aided therapy.
Abbreviations: PD, Parkinson’s disease; LCIG, levodopa–carbidopa intestinal gel; 
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modified to include more first-hand patient experiences, and 
to include more practical information.44
ParkinsonNet has not only provided more joined-up care 
for people with PD centered around evidence-based recom-
mendations and best practice guidelines, but also reduced 
health care costs by approximately €20 million each year, 
illustrating that informed patients make the right decisions.45
The Düsseldorf Parkinson MDT 
network approach in Germany improves 
MDT communication and increases 
the individual with PD’s confidence in 
innovative therapies
The Düsseldorf Parkinson network is another approach to 
the MDT management of PD.46 A university-hospital–based 
MDS together with a PDNS and a general neurologist jointly 
see and discuss patients attending the general neurologist’s 
outpatient clinic. A diagnostic and therapeutic treatment 
strategy, such as planning an advanced therapy, can usually 
be developed at the time. This leads to greatly improved 
interaction and communication between experts from the 
Movement Disorders Center and the general neurologist; 
and involvement of the general neurologist increases the 
individual with PD’s confidence in innovative therapeutic 
options. Treatment can then be initiated promptly to improve 
the individual’s QoL.
After the joint outpatient consultation, the diagnostic 
and therapeutic procedures are carefully planned in close 
consultation with the cooperating specialized disciplines (eg, 
gastroenterology for LCIG, neurosurgery for DBS) before 
the patient’s admission to ensure optimal resource utilization 
and effective clinical treatment.
The network has recently incorporated an integrated care 
contract, which includes the following approaches:
1. If the patient agrees to a proposed hospital admission, 
for example, to carry out LCIG therapy or DBS, then 
the patient’s data are forwarded to the patient manager of 
the university hospital. The patient manager immediately 
arranges the inpatient stay, the relevant interdisciplinary 
consultation with other specialized disciplines (eg, gas-
troenterology, neurosurgery), and the admission appoint-
ment with the patient by telephone.
2. After the procedure, the patient is usually seen again at 
a joint consultation with their general neurologist, the 
MDS, and the PDNS to discuss and manage the new 
treatment. The PDNS may visit the patient at home up 
to four times during a 12-month period to offer further 
education or assistance in the handling of an invasive PD 
therapy.
3. The patient may receive a telemedicine care program,47 in 
which case patient-related data are passed to the autho-
rized PDNS, who then schedules a 4-week treatment 
period after consulting the insurance provider and the 
patient.
Implementing LCIG therapy
LCIG is an effective treatment option for advanced PD that 
significantly improves patients QoL and motor fluctuations. 
It is approved for the treatment of advanced levodopa-respon-
sive PD with severe motor fluctuations and hyperkinesia/dys-
kinesia when available combinations of Parkinson medicinal 
products have not given satisfactory results.48 For long-term 
administration, LCIG is administered with a portable pump 
directly into the jejunum by a percutaneous endoscopic 
gastrostomy49 with a jejunal extension tube (PEG-J).48,50 
This alleviates the pharmacokinetic issues associated with 
oral levodopa–carbidopa, bypassing the often erratic gastric 
emptying in advanced PD.35 The PEG-J procedure requires 
close cooperation between the MDS, a gastroenterologist 
skilled in carrying out the procedure in patients with PD, and 
nurses in the neurology and gastroenterology departments.
Accessibility to the gastroenterologist, whose expertise 
is required before, during, and after the procedure, and to 
deal with any problems or questions that might arise, is key. 
Some gastroenterologists may not be familiar with the PEG-J 
tubing and connections required for LCIG therapy, and so 
time will be required for:
1. familiarization with the equipment and 
2. to develop understanding of the dyskinesias that occur in 
PD to ensure they do not interfere with the procedure.
It is important to optimize PD medication before PEG-J 
placement in order to achieve a balance between patient 
rigidity and dyskinesia, and facilitate insertion.51,52
The PDNS ensures coordination between the person with 
PD, the caregiver, and all members of the MDT before, dur-
ing, and after the procedure. It is useful to have an established 
protocol. In one center in Madrid, Spain (Hospital General 
Universidad Gregorio Marañón ), a one-page wall-mounted 
illustrated protocol clarifies nursing roles and responsibilities 
throughout the titration process (Figure 2).
In Denmark, the nurses in the neurology department take 
much of the postprocedural responsibility and are trained to 
manage the PEG-J, though can seek assistance from nurses 
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MDT management for advanced PD





















Day 2 Day 3 Day 4
Gastrointestinal phase
Introduction
Parkinson’s is a chronic neurodegenerative disease that affects the neurons in the substantia nigra. A
decrease in the availability of dopamine occurs. The result is the appearance of resting tremor, muscle
rigidity, and bradykinesia. In the case of advanced Parkinson's disease that is not controlled with conventional
treatment, LCIG can be used. It consists of the continuous administration of levodopa/carbidopa gel
(20/5 mg per mL), via the intestine, by means of an infusion pump.
During hospitalization, coordination is necessary between professionals of different areas: the
neurologist, the gastroenterologist, and nurses. With this motive, the clinical pathway has been
developed, where protocols of these professionals are collected.
In the following table, the nursing activities in the clinical pathway are described:
Conclusion
Multidisciplinary care is the key to the comprehensive management of advanced Parkinson's disease, especially in
the case of unconventional therapies such as LCIG. Developing a clinical pathway improves the implementation of
treatment and therefore the patients' quality of life. LCIG pump is not the solution to everything, but it represents






Phase for checking the adaptation of
the patient to the treatment
Evaluation for 
admission






  and gastrostomy)
• LCIG
Check laboratory 
tests, ECG, chest X-ray
Diet rich in fiber Semisoft diet
Fasting state from
24 hours




Adherence to the treatment and prevention of complications are essential to ensure the success of the therapy.
Soft diet Regular diet
Request an abdominal




(from control to 23 hours)
after dose calculation
and pump programming
DO NOT WASH THE
TUBING AFTER THE
INFUSION.








Daily care of the
stoma with saline and
antiseptic
(chlorhexidine)



















(from 7 to 23 hours)
Conventional medication
LCIG pump
(from 7 to 23 hours)
Antibiotic amoxicillin/














Phase for PEG implementation, titration,
and patient discharge
Antibiotic before PEG
(cefazolin 2 g IV or
levaflaxacin 500 mg if
allergy)
Figure 2 The one-page, wall-mounted illustrated titration protocol clarifying the role and responsibilities of nurses throughout the titration process at the Hospital General 
Universitario Gregorio Marañón, Madrid, Spain.
Notes: This poster is one component of the hospital’s “clinical pathway” that coordinates the protocols for each role in the MDT. Steps of this protocol reflect regional use 
and not necessarily label instructions for this product. Courtesy from Drs Carmen Funes Molina and Francisco Grandas, (translated from Spanish).
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and their caregiver are trained to handle the pump and the 
practicalities of the treatment. They are also provided with 
contact numbers for specially trained community nurses and 
the hospital-based PDNS, along with advice about who to 
call and when.
At German model institutions, experience has shown 
that it is essential that the collaborating gastroenterologist 
is a skilled interventional endoscopist who is familiar with 
the procedure, the pitfalls, and the potential complications. 
Before starting the 2-day test phase with a nasointestinal tube, 
PD patients are routinely examined using fiberendoscopic 
evaluation of swallowing, videofluoroscopy, functional 
transnasal endoscopy to investigate the esophageal phase 
of deglutition,53 high-resolution manometry, and endoscopy 
to assess the feasibility of the PEG-J procedure. However, 
most PEG-J placements worldwide are performed without 
this extensive workup.
Following standard operating procedures, and after a 
single dose of antibiotic intravenously, at least a transab-
dominal ultrasound should be performed to exclude anatomic 
problems, after which both nasointestinal tubes and PEG-J are 
placed on an inpatient basis. After successful implementation 
of the treatment, the patients are followed up in hospital, and 
at discharge, they are provided with domestic nursing staff 
to provide professional assistance.
A Canadian outpatient model 
significantly reduces the burden on 
limited health care resources
In Canada, an outpatient ambulatory model significantly 
reduces the cost for initiating LCIG and the burden on lim-
ited health care resources. It also offers greater flexibility in 
scheduling because it does not depend on the availability of 
an inpatient bed.54
In this model, a gastroenterologist is an integral part of the 
MDT and carries out a preprocedure consultation to screen 
for contraindications, to provide information on the inser-
tion process and the risks and complications, and to obtain 
consent. The LCIG nurse (a hospital PD nurse trained in the 
LCIG pump system and titration) provides further informa-
tion on the PEG-J and aftercare.
The PEG-J procedure is carried out on the outpatient 
endoscopy unit. The patient is under conscious sedation or 
given propofol for deep sedation, depending on clinician’s 
judgment and the level of dyskinesia. This involves close col-
laboration between the gastroenterologist, anesthesiologist, 
and movement disorder team. Appropriate placement of the 
J-tube is confirmed using a portable abdominal X-ray with 
contrast injected into the J-tube. The patient is discharged 
from the unit on recovery from the sedation. The next day, the 
gastroenterologist examines the stoma and confirms correct 
placement of the PEG-J in the ambulatory clinic.
Once the fistula tract of the PEG-J has matured, the patient 
returns for outpatient medication titration over a few days. 
The LCIG nurses titrate the LCIG dosage under the supervi-
sion of the neurologist and take a lead role in managing the 
pump; they are trained in basic stoma care and supported by 
the gastroenterologist.
The patients are followed up every 3 or 6 months, and the 
gastroenterologist examines the stoma and PEG-J placement 
at each visit.
It has proved beneficial for the trained gastroenterologist 
to train gastroenterologists in other centers and share best 
practices and learnings.
One consideration of this outpatient model is that patients 
who live at some distance from the health care center may find 
it difficult to attend the ambulatory clinic the following day and 
during the initial LCIG titrating phase. This can be overcome 
by providing accommodation in nearby housing or a hostel.
Discussion
The multifaceted nature of PD naturally lends itself to a 
multidisciplinary approach to care.55 A well-structured MDT 
can provide essential support in many areas of disease man-
agement, for example, with therapy decisions, which can 
become more complex as the disease progresses. Raising 
awareness about when a person with PD might benefit from 
an advanced therapy is a key responsibility for both the MDS 
and PDNS. The PDNS and MDS aim to align the expecta-
tions of the person with PD and their caregiver with what 
can be achieved from a particular type of advanced therapy. 
Through “participatory medicine” it is crucial that the MDT, 
while empowering people with PD and their caregivers to 
take an active role in management of their disease, provide 
unbiased information and advice as and when appropriate, 
tailoring it to the individual.28
Available studies show that people with PD and their 
caregivers benefit from joined-up multidisciplinary care, 
although the number of reports in this area is still limited 
and very few controlled studies are available.1–8,10,11,56–58 
The key to the optimal management of people with PD at 
all stages of the disease, and successful implementation of 
advanced therapies, is an effective MDT approach, such 
as those models described in this paper. An optimal MDT 
structure can provide benefits for the patient and his or her 


































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




MDT management for advanced PD
With the increasing prevalence and burden of PD, and rising 
health care costs, the financial implications of such models 
are ever more important. In the Netherlands, regional MDTs 
that specialize in providing a particular type of advanced PD 
therapy (ParkinsonNet)42 have not only improved the quality 
of care but also decreased health care costs.43 In Germany, the 
Düsseldorf Parkinson network has led to greatly improved 
interaction and communication between experts from the 
Movement Disorders Center and the general neurologist, 
enabling more efficient initiation of advanced therapies. In 
Canada, the outpatient ambulatory model has been estab-
lished for LCIG onboarding, to overcome the challenge and 
cost of obtaining inpatient beds.
Intensive multidisciplinary rehabilitation interventions 
for people with PD are particularly effective at improving 
QoL and motor function.1–8,10,11,56–58 Although investment in 
such initiatives might prevent future costs attributed to dis-
abling motor symptoms (eg, falls, loss of independence),58 
innovative solutions should be considered to ensure such 
interventions can continue in the long-term, such as the 
Düsseldorf Parkinson network telemedicine care program. 
Not only do telemedicine approaches offer cost savings, 
they also have the benefit of opening up multidisciplinary 
care for people with PD who have limited access to special-
ist centers.59 While there are few studies of telemedicine in 
PD, schemes are on the increase enabling a better standard 
of care for patients in their homes or in remote areas.59,60 
Furthermore, valid remote assessments of people with PD 
have been performed, and a high degree of patient satisfac-
tion was reported with these studies.59,60
There is no “one-size-fits-all” approach to multidisci-
plinary care for people with PD; however, the models and 
studies discussed in this review may be adapted on a country/
region/area basis. In countries lacking specialist MD services, 
a smaller, more localized MDT may be more realistic, with 
skilled physicians, who have experience in PD, initiating 
advanced therapies. Flexibility around implementing such 
approaches will increase access to multidisciplinary care 
for more people with PD, subsequently improving disease 
management, and ultimately patient and caregiver QoL.
Limitations
Limitations of this review include the lack of a systematic 
literature search to identify relevant studies. Furthermore, 
very few published, controlled studies exist to quantify the 
effect on multidisciplinary interventions in PD. Finally, there 
is a lack of clinical guidelines in the subject area; hence, the 
recommendations provided here are informed by the clinical 
experience of the authors.
Conclusion
The advantages of an MDT approach are clear and have 
been documented in several small studies, but larger scale, 
controlled trials are required to fully understand the benefits. 
Given the chronic nature of PD, and the difficulties many 
patients face traveling to appointments, particularly those 
with advanced disease, it is imperative that future studies 
consider innovative approaches to enable wider access to 
MDT care.
Based on the available literature and expert clinical 
experience of authors, key recommendations for the MDT 
approach for people with PD are:
1. to set up a close structured collaboration of different 
health care professionals working in a fixed network 
structure;
2. to refer people with PD to established MDT centers 
(where available) in a timely manner;
3. to establish regular meetings with treatment-responsible 
doctors and the MDT for interdisciplinary exchange and 
learning to optimize individual treatment and evaluate 
treatment options;
4. to ensure treatment decisions are agreed jointly between 
people with PD, their caregiver, family, and health care 
professional;
5. to include specialists outside of neurology from adjuvant 
medical departments as necessary when implementing 
advanced therapies.
Finally, the PDNS, a robust practical protocol that states 
who is doing what and when, and an effective network involv-
ing the community neurologist for training or consultation 
purposes are also pivotal to the success of the PD MDT.
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